- ISO 11607 is the globally harmonized standard for packaging terminally sterilized medical devices, covering both materials (Part 1) and process validation (Part 2).
- Compliance with ISO 11607 satisfies both FDA 21 CFR Part 820 requirements and EU MDR Annex I general safety and performance requirements.
- A sterile barrier system (SBS) must maintain sterility from point of manufacture through to the point of aseptic presentation to the end user.
- Packaging validation under ISO 11607-2 follows a three-phase approach: installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ).
- Comprehensive documentation — including risk analysis, material specifications, test reports, and aging studies — is mandatory and subject to regulatory audit.
ISO 11607 is the international standard that defines how medical device manufacturers must design, test, and validate packaging for terminally sterilized medical devices. If your device requires sterility at the point of use, ISO 11607 compliance is not optional — it is a prerequisite for regulatory clearance in the United States, the European Union, and most other regulated markets worldwide.
This guide covers the full scope of ISO 11607 — its two-part structure, material and process validation requirements, regulatory recognition, testing obligations, and documentation standards — to help quality and regulatory professionals navigate compliance efficiently.
What Is ISO 11607?
ISO 11607, formally titled Packaging for terminally sterilized medical devices, specifies requirements for materials, sterile barrier systems, protective packaging, and processes used in packaging medical devices that will be sterilized after packaging. It was developed by ISO Technical Committee 198 and is maintained in two parts, both of which were most recently revised in 2019.
The standard applies to any medical device that is intended to be supplied in a sterile state and that is sterilized by a validated terminal sterilization process. This includes devices sterilized by ethylene oxide (EtO), gamma irradiation, electron beam, steam, and other recognized modalities.
The core purpose of ISO 11607 is straightforward: to ensure that a sterile barrier system (SBS) effectively protects a medical device against microbial contamination from the moment of packaging through to the point of aseptic presentation to the clinician or end user. Any failure in that chain — whether at the material level, the sealing process, or the distribution phase — constitutes a patient safety risk.
ISO 11607 Part 1: Materials and Sterile Barrier Systems
ISO 11607-1 establishes requirements for materials, preformed sterile barrier systems, sterile barrier systems, and packaging systems. It defines what constitutes an acceptable sterile barrier and specifies the performance properties those materials and systems must demonstrate.
Sterile Barrier System (SBS) Definition
An SBS is the minimum packaging that minimizes the risk of ingress of microorganisms and allows aseptic presentation of the device at the point of use. The SBS typically consists of the primary packaging that is in direct contact with or closest to the sterile device — for example, a Tyvek-lidded tray, a peel pouch, or a formed blister. The SBS must be distinguishable from any outer protective packaging.
Material Requirements
| Requirement Category | What Must Be Demonstrated | Relevant Test Standards |
|---|---|---|
| Microbial barrier | Material prevents microbial ingress after sterilization | ASTM F1608, EN ISO 11607-1 Annex C |
| Sterilization compatibility | No degradation under intended sterilization process(es) | ISO 11135, ISO 11137, EN 556 |
| Biocompatibility | No toxic or harmful extractables/leachables | ISO 10993 series |
| Physical and chemical properties | Tensile strength, porosity, chemical resistance, cleanliness | ASTM D882, ISO 5636-5 |
| Stability (aging) | Maintains barrier performance over claimed shelf life | ASTM F1980 (accelerated aging) |
| Toxicological safety | Inks, adhesives, coatings do not pose patient risk | ISO 10993-7, REACH |
| Labeling legibility | All labeling remains legible over the claimed shelf life | ISO 15223-1 |
Packaging System Design
ISO 11607-1 also requires that the packaging system design be evaluated against the intended use environment and distribution conditions. This includes consideration of storage temperature and humidity ranges, transportation stresses (vibration, drop, compression), and handling by healthcare workers during aseptic opening.
ISO 11607 Part 2: Validation of Forming, Sealing and Assembly Processes
ISO 11607-2 specifies validation requirements for the industrial processes used to form, seal, and assemble sterile barrier systems. The central principle is that manufacturing processes that directly affect the integrity of the SBS must be validated — not merely monitored — to demonstrate that they consistently produce compliant output.
Installation Qualification (IQ)
IQ verifies that equipment has been installed correctly and in accordance with the manufacturer's specifications. It covers calibration, utility connections, safety systems, and documentation of baseline equipment parameters. IQ establishes that the equipment is capable of operating within defined specifications before process development begins.
Operational Qualification (OQ)
OQ demonstrates that the process operates within defined limits throughout the established operating range. For heat sealing, this means defining and validating the process window — the combination of temperature, dwell time, and pressure that consistently produces seals meeting acceptance criteria at both the high and low ends of the operating range. OQ challenges the process at its extremes, not just at the nominal set point.
Performance Qualification (PQ)
PQ confirms that the validated process produces consistently compliant output under actual or simulated production conditions. PQ is conducted using production-representative materials, equipment settings within the validated process window, and the full range of personnel, shifts, and environmental conditions encountered in routine manufacturing. PQ data form the statistical basis for process capability claims.
ISO 11607-2019 (both parts) is recognized by the FDA as a consensus standard under 21 CFR 820 and is listed in the FDA's Database of Recognized Consensus Standards. In the EU, it is harmonized under the Medical Device Regulation (EU) 2017/745 (MDR), meaning compliance creates a presumption of conformity with applicable GSPRs in MDR Annex I. Manufacturers are strongly advised to document reliance on these standards in their technical documentation filed with their Notified Body.
Regulatory Recognition: FDA and EU MDR
ISO 11607 occupies a privileged position in the global regulatory landscape. In the United States, the FDA recognizes ISO 11607-1:2019 and ISO 11607-2:2019 as consensus standards. When a 510(k) or PMA submission references these standards, the FDA expects documented evidence of conformity in the design history file or device master record.
In the European Union, both parts of ISO 11607 are harmonized under EU MDR (Regulation 2017/745). Compliance with ISO 11607 addresses essential requirements related to sterile barrier integrity, packaging labeling, and shelf life — all of which are relevant General Safety and Performance Requirements (GSPRs) in MDR Annex I. For CE marking purposes, manufacturers must include a Declaration of Conformity to ISO 11607 in their technical documentation and ensure their Notified Body has reviewed packaging validation evidence.
It is also worth noting that the new EU Packaging and Packaging Waste Regulation (PPWR, EU 2025/40), applicable from August 2026, contains specific carve-outs for sterile medical device packaging. Packaging that is contact-sensitive for sterility purposes is exempt from the 2030 recyclable design mandate pending a review in 2035, reflecting the regulators' recognition that sterility requirements take precedence over recyclability targets for this category.
Key Testing Requirements Under ISO 11607
A comprehensive ISO 11607 test program covers three major domains: seal integrity and strength, whole-package integrity, and aging and distribution performance.
Seal Integrity and Strength Testing
Seal strength is measured by peel testing (ASTM F88) and expressed in N/15mm or N/25mm. Acceptance criteria must be defined based on clinical risk and validated during OQ/PQ. Seal integrity — absence of channels, pinholes, or defects — is assessed by dye penetration (ASTM F1929 for porous substrates, ASTM F3039 for non-porous) or bubble emission testing (ASTM F2096). For a detailed comparison of seal integrity testing methods, see our guide to seal integrity testing.
Package Integrity Testing
Whole-package integrity testing evaluates whether the complete SBS is free of leaks that could allow microbial ingress. Non-destructive methods include vacuum decay (ASTM F2338), pressure decay, and tracer gas methods. These deterministic approaches are increasingly preferred by regulators over probabilistic methods such as dye ingress.
Aging and Distribution Testing
ISO 11607 requires that packaging maintain its performance characteristics over the claimed shelf life and through the expected distribution environment. Accelerated aging per ASTM F1980 compresses real-time equivalent aging into a feasible study period. Distribution simulation testing per ASTM D4169 or ISTA protocols verifies that the SBS survives the mechanical stresses of shipping and handling without integrity loss. For a full guide to accelerated aging protocols, see our ASTM F1980 accelerated aging guide.
Documentation Requirements
A complete packaging validation file must include: a risk analysis per ISO 14971; design inputs and outputs; material specifications and Certificates of Analysis; IQ/OQ/PQ protocols and executed reports; aging and distribution study reports; labeling verification records; and change control documentation. Regulatory inspections and Notified Body audits routinely examine packaging validation files. Incomplete documentation is among the most common sources of FDA 483 observations in sterile device manufacturer inspections.
"Packaging validation is not a one-time event — it is a living program. Changes to materials, equipment, suppliers, or sterilization processes can all require partial or complete re-validation. A robust change control system is as important as the initial validation itself."
Common Compliance Gaps
Inspection trends and notified body feedback consistently identify the following ISO 11607 compliance gaps: insufficient process window definition in OQ (validating only a single set point rather than a range); aging studies conducted at temperatures that do not reflect worst-case storage conditions; missing or inadequately controlled incoming material inspection procedures; failure to re-validate after equipment changes, supplier changes, or facility moves; and inadequate traceability between risk analysis acceptance criteria and validation test acceptance criteria. Manufacturers building packaging validation programs from the ground up should design their validation protocols with auditor scrutiny explicitly in mind. Choosing compliant materials is also foundational — our Tyvek medical packaging guide covers material selection considerations in depth.
Frequently Asked Questions
Does ISO 11607 apply to all medical devices?
ISO 11607 applies specifically to medical devices that are terminally sterilized — sterilized in their final packaging configuration. Devices processed (cleaned and sterilized) by the healthcare facility prior to use are governed by different standards, such as ISO 17664. If your device is supplied sterile and must remain sterile until opened by the clinician, ISO 11607 applies.
What is the difference between ISO 11607-1 and ISO 11607-2?
ISO 11607-1 defines what the packaging must achieve — performance requirements for materials, sterile barrier systems, and protective packaging. ISO 11607-2 defines how the packaging must be manufactured — validation requirements for the industrial processes (forming, sealing, assembly) used to produce the sterile barrier system. Both parts must be addressed in a complete compliance program.
Is ISO 11607 compliance mandatory for CE marking under EU MDR?
ISO 11607 is harmonized under EU MDR (Regulation 2017/745), meaning compliance creates a presumption of conformity with specific GSPRs in Annex I. While technically voluntary, the standard represents the accepted industry method for demonstrating sterile packaging compliance. In practice, Notified Bodies expect ISO 11607 validation documentation during technical file review.
How long does a packaging validation typically take?
A complete packaging validation program — including IQ/OQ/PQ, accelerated aging (typically 40–90 days at 55°C to simulate 1–3 years), and distribution simulation — typically takes 3 to 6 months from protocol development to final report. Real-time aging studies run concurrently over the full claimed shelf life.
Can a packaging validation be transferred to a new manufacturing site?
A site transfer typically requires at minimum an IQ/OQ/PQ re-validation at the new site, since equipment, utilities, and environmental conditions will differ. Depending on the extent of changes, a full re-validation may be required. The ISO 14971 risk assessment should drive the scope of re-validation activity.
What happens if a packaging process changes after validation?
Any change to validated packaging processes — including materials, equipment, process parameters, or suppliers — must be assessed under change control. The assessment determines whether the change could affect packaging performance, and if so, triggers appropriate re-qualification or re-validation per ISO 11607-2 Section 5.3.
Where can I find the official ISO 11607 standard documents?
The official standards are available for purchase from the ISO online store (Part 1) and ISO 11607 Part 2. National standards bodies such as ANSI (USA), BSI (UK), and DIN (Germany) also distribute ISO standards. ASTM International publishes complementary test method standards extensively referenced within ISO 11607.